资讯

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...
Serena Williams wants to be transparent and is opening up about her fitness journey, revealing she's taking a GLP-1 ...
一种新的肥胖症治疗方法不再以神经元为靶点,而是针对大脑中的支持细胞,从而在不引起恶心的情况下实现减重和更好的血糖控制。人体试验有望在几年内开始。 目前市场上的减肥和糖尿病药物通常无法帮助患者实现长期减重。胰高血糖素样肽-1(Glucagon-like ...
Novel Glucagon like peptide-1 (GLP-1) drugs were designed and industrial prepared by researchers from Hefei Institutes of Physical Science, Chinese Academy of Sciences Through molecular design ...
The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%.
DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...
The metabolism of GLP-1 in the body is extremely rapid and the peptide gets inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), even before leaving the gut. 3 Glucagon is a key hormone in ...
Correspondence Glucagon-like Peptide 1–Receptor Scans to Localize Occult Insulinomas Published August 14, 2008 N Engl J Med 2008;359: 766 - 768 DOI: 10.1056/NEJMc0802045 ...
Some studies have reported reduced secretion of glucagon-like peptide-1 (GLP-1) in patients with type 2 diabetes mellitus; however, other studies have failed to find such an association. The ...
Overview of Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes Richard E. Pratley, MD Disclosures Medscape J Med. 2008;10 (7):171 0 ...
COMMENTARY Glucagon-like Peptide 1: Incretin, Glucose Regulatory Hormone, and Diabetes Treatment, Part II Torsten P. Vahl, MD; David A. D'Alessio MD Disclosures May 07, 2004 0 ...